{"anticipatedPostingDate":"2028-07","denomUnitsSelected":"Participants","description":"Time to treatment failure is defined as time to end of study randomized treatment (except for hematopoietic stem cell transplantation \\[HSCT\\] without loss of MRD-negative CR) due to safety and efficacy reasons. MRD-negative CR is achieved when a participant meets the criteria for both MRD negativity and CR. MRD-negativity: \\<=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with \\>=10,000 ABL1 transcripts. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and \\<5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC \\>1000/mcL (or \\>1.0\\*10\\^9/L). 5. Platelets \\>100,000/mcL (or \\>100\\*10\\^9/L).","reportingStatus":"NOT_POSTED","timeFrame":"Up to approximately 6 years","title":"Time to Treatment Failure","type":"SECONDARY"}